Detailed Notes on M3541
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate many intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Most important demo targets had been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis su